AstraZeneca, which is developing the possible vaccine along with the University of Oxford, said adverse responses to the vaccine among the elderly were found to be lower.
“The results further build the body of evidence for the safety and immunogenicity of [the vaccine].”
Oxford and AstraZeneca said that data from the analysis was submitted to a peer-reviewed journal, although it's not clear when a study could be published.
Oxford is the sponsor of the CCP (Chinese Communist Party) virus trials in the United Kingdom, while AstraZeneca is the sponsor in the United States. In the United States, the trials were delayed in September and in most of October to quell safety questions.
"In each of these cases, after considering the information, the independent reviewers recommended that vaccinations should continue. Close monitoring of the affected individuals and other participants will be continued. With any new medicine or vaccine there is always a possibility of an unexpected side effect," the sheet said.
On Oct. 23, AstraZeneca was given the go-ahead to restart the vaccine trial in the United States by federal regulators. The U.S. Food and Drug Administration is investigating whether the vaccine could be linked to adverse side effects.